(VIANEWS) – Catalyst Pharmaceuticals (CPRX), Martin Marietta Materials (MLM), Apollo Medical Holdings (AMEH) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Catalyst Pharmaceuticals (CPRX)
19.3% sales growth and 20.06% return on equity
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Earnings Per Share
As for profitability, Catalyst Pharmaceuticals has a trailing twelve months EPS of $0.55.
PE Ratio
Catalyst Pharmaceuticals has a trailing twelve months price to earnings ratio of 26.28. Meaning, the purchaser of the share is investing $26.28 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.06%.
Sales Growth
Catalyst Pharmaceuticals’s sales growth is 74.1% for the current quarter and 19.3% for the next.
Yearly Top and Bottom Value
Catalyst Pharmaceuticals’s stock is valued at $14.45 at 19:22 EST, way below its 52-week high of $22.11 and way higher than its 52-week low of $11.09.
2. Martin Marietta Materials (MLM)
17.6% sales growth and 14.93% return on equity
Martin Marietta Materials, Inc., a natural resource-based building materials company, supplies aggregates and heavy-side building materials to the construction industry in the United States and internationally. It offers crushed stone, sand, and gravel products; ready mixed concrete and asphalt; paving products and services; and Portland and specialty cement for use in the infrastructure projects, and nonresidential and residential construction markets, as well as in the railroad, agricultural, utility, and environmental industries. The company also produces magnesia-based chemicals products; dolomitic lime primarily to customers for steel production and soil stabilization; and cement treated materials. Its chemical products are used in flame retardants, wastewater treatment, pulp and paper production, and other environmental applications. Martin Marietta Materials, Inc. was founded in 1939 and is headquartered in Raleigh, North Carolina.
Earnings Per Share
As for profitability, Martin Marietta Materials has a trailing twelve months EPS of $17.7.
PE Ratio
Martin Marietta Materials has a trailing twelve months price to earnings ratio of 28.17. Meaning, the purchaser of the share is investing $28.17 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.93%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 30.6% and 15.3%, respectively.
Sales Growth
Martin Marietta Materials’s sales growth is 19% for the current quarter and 17.6% for the next.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Martin Marietta Materials’s EBITDA is 4.96.
Volume
Today’s last reported volume for Martin Marietta Materials is 227121 which is 39.77% below its average volume of 377122.
3. Apollo Medical Holdings (AMEH)
17.2% sales growth and 9.76% return on equity
Apollo Medical Holdings, Inc., a physician-centric technology-powered healthcare management company, provides medical care services. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The company's physician network consists of primary care physicians, specialist physicians, and hospitalists. It serves patients, primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization plans; and non-insured patients in California. The company was founded in 1994 and is headquartered in Alhambra, California.
Earnings Per Share
As for profitability, Apollo Medical Holdings has a trailing twelve months EPS of $1.04.
PE Ratio
Apollo Medical Holdings has a trailing twelve months price to earnings ratio of 31.84. Meaning, the purchaser of the share is investing $31.84 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.76%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 9.8%, now sitting on 1.33B for the twelve trailing months.
Sales Growth
Apollo Medical Holdings’s sales growth is 13.6% for the present quarter and 17.2% for the next.
4. Sapiens International Corporation N.V. (SPNS)
9.2% sales growth and 14.84% return on equity
Sapiens International Corporation N.V. provides software solutions for the insurance and financial services industries in North America, Europe, the Asia Pacific, and South Africa. The company offers Sapiens CoreSuite and Sapiens IDITSuite for personal, commercial, and specialty lines, as well as reinsurance and workers' compensation; and Sapiens CoreSuite, Sapiens UnderwritingPro, Sapiens ApplicationPro, Sapiens IllustrationPro, and Sapiens ConsolidationMaster for life, pension, and annuities. It also provides Sapiens DigitalSuite for insurance customers, agents, brokers, risk managers, customer groups and third-party service providers; Sapiens AgentConnect and Sapiens CustomerConnect portals; Sapiens Intelligence, an analytics platform; Sapiens IntelligencePro, a comprehensive BI solution with pre-configured reports, dashboards, and scorecards; and Sapiens Advanced Analytics, which uses AI and Machine Learning to generate actionable insights based on different models across the insurance value chain. In addition, the company offers Sapiens ReinsuranceMaster, Sapiens ReinsurancePro, and Sapiens Reinsurance GO reinsurance solutions; and Sapiens Platform, Sapiens CoreSuite, Sapiens PolicyPro, and Sapiens ClaimsPro, as well as Sapiens PolicyGo, Sapiens ClaimsGo, and Sapiens Connect for workers' compensation. Further, it provides financial and compliance solutions, which comprise Sapiens FinancialPro, Sapiens Financial GO, Sapiens StatementPro, Sapiens CheckPro, and Sapiens Reporting Tools; and Sapiens Decision, an enterprise-scale platform that enables institutions to centrally author, store, and manage various organizational business logics. Additionally, the company offers tailor-made solutions based on its Sapiens eMerge platform; and program delivery, business, and managed services. It markets and sells its products and services through direct and partner sales. The company was founded in 1982 and is headquartered in Holon, Israel.
Earnings Per Share
As for profitability, Sapiens International Corporation N.V. has a trailing twelve months EPS of $1.05.
PE Ratio
Sapiens International Corporation N.V. has a trailing twelve months price to earnings ratio of 24.69. Meaning, the purchaser of the share is investing $24.69 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.84%.
5. Visteon Corporation (VC)
6.3% sales growth and 23.03% return on equity
Visteon Corporation engineers, designs, and manufactures cockpit electronics and connected car solutions for vehicle manufacturers worldwide. The company provides instrument clusters, including standard analog gauge clusters to high-resolution, all-digital, fully reconfigurable, 2-D, and 3-D display-based devices; information displays that integrate a range of user interface technologies and graphics management capabilities; and audio and infotainment systems that allows vehicle occupants to connect their mobile devices to the system and safely access phone functions, listen to music, stream media, and enable mobile connectivity applications. It also offers infotainment solutions, including Phoenix display audio and embedded infotainment platform; telematics control unit to enable secure connected car services, software updates, and data; SmartCore, an automotive-grade, integrated domain controller to enhance efficiency, and reduce power consumption and cost; and head-up displays (HUD), such as combiner HUD and windshield HUD that present critical information to the driver. Visteon Corporation was founded in 2000 and is headquartered in Van Buren, Michigan.
Earnings Per Share
As for profitability, Visteon Corporation has a trailing twelve months EPS of $5.39.
PE Ratio
Visteon Corporation has a trailing twelve months price to earnings ratio of 22.49. Meaning, the purchaser of the share is investing $22.49 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.03%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 1.2%, now sitting on 4.03B for the twelve trailing months.
Yearly Top and Bottom Value
Visteon Corporation’s stock is valued at $121.20 at 19:22 EST, way under its 52-week high of $171.66 and way higher than its 52-week low of $108.66.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Visteon Corporation’s EBITDA is 0.83.
Volume
Today’s last reported volume for Visteon Corporation is 385123 which is 23.5% above its average volume of 311834.
